Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Thistle and Reduced Gamma-Glutamyl Transpeptidase Level

Doses used in studies

mg/day: 103.2 (median 103.2, IQR 103.2–103.2) — 1 study

Time to effect

Median: 5.6 months · IQR 5.6 months–5.6 months · Range 5.6 months–5.6 months — Reported in 1 of 1 study

1 of 1 paper

Silymarin decreases liver stiffness associated with gut microbiota in patients with metabolic dysfunction-associated steatotic liver disease: a randomized, double-blind, placebo-controlled trial.
- 2024-08-03
- RCT · n = 83
- Lipids in health and disease 23(1)
- - Yufeng Jin
  - Xin Wang
  - Ke Chen
  - Yu Chen
  - Lixin Zhou
  - Yupeng Zeng
  - Yuqing Zhou
  - Zhijun Pan
  - Di Wang
  - Zhongxia Li
  - Yongqian Liang
  - Wenhua Ling
  - Dan Li
- PubMed: 39097726
- DOI: 10.1186/s12944-024-02220-y
19 Insights on
- Reduced Gamma-Glutamyl Transpeptidase Level
- High evidence
- Clinical
and serum levels of γ-glutamyl transpeptidase (GGT, -8.21 ± 3.01 vs. 1.23 ± 3.16, P = 0.042)
Effect
Beneficial
Effect size
Small
Significant
Yes
Dose
103.2 mg/d